文章

 肝病研究中心

主持人:胡志棠 Chi-Tan Hu

聯絡資訊: 03-8561825#15734
E-mail:Email住址會使用灌水程式保護機制。你需要啟動Javascript才能觀看它

主持人簡介:

Professor Hu completed his MD from Taipei Medical University, Taipei, Taiwan, PhD from Cambridge University, UK and postdoctoral studies from National Institute of Health, Bethesda, Maryland, USA. His research interests are on transnasal endoscopy, Helicobacter Pylori, irritable bowel syndrome and hepatocellular carcinoma. He has published more than 100 papers in international journals.

 

現職:花蓮慈濟醫院內科部肝膽腸胃科主治醫師、花蓮慈濟醫院內科部肝膽腸胃研究中心主任、慈濟大學醫學系副教授
學歷:台北醫學大學醫學士、英國劍橋大學分子生物學博士
研究興趣/研究主題/研究方向/專長:慢性肝炎、肝硬化、肝癌腸胃道發炎、幽門桿菌感染治療治療、分子生物學、分子遺傳學、遺傳病及癌症的分子醫學診斷、經鼻內視鏡、換水法大腸鏡

 

近期研究著作:

1. Chi-Tan Hu*. Cotton pledget packing versus topical spray for nasal preparation: merits and demerits are answered by a strict randomized controlled trial. European Archives of Oto-Rhino-Laryngology270(5):1763-1764. 2013 May. (SCI)
2. Chi-Tan Hu, Chuan-Chu Cheng, Siou-Mei Pan, Jia-Ru Wu, Wen-Sheng Wu*. PKC mediates fluctuant ERK-paxillin signaling for hepatocyte growth factor-induced migration of hepatoma cell HepG2. Cellular Signalling 25(6):1457–1467, 2013 Jun. (SCI)
3. Chi-Tan Hu, Jia-Ru Wu, Wen-Sheng Wu*. The role of endosomal signaling triggered by metastatic growth factors in tumor progression. Cellular Signalling 25(7):1539-1545. 2013 Jul. (SCI)
4. Wen-Lin Lo, Jen-Shung Lin, Wei-Yi Lei, Hao-Chun Yu, Li-Keng Chao, Jui-Sheng Hung, Daw-Chian Tang, Chi-Tan Hu*. Transnasal Endoscopy: Savior for Patients with Endoscopy Phobia. Journal of Internal Medicine of Taiwan 24(4):271-277. 2013 Aug.
5. Chi-Tan Hu*. Let your patients watch and talk during examination: A review of unsedated transnasal endoscopy. Tzu Chi Medical Journal 25(3):139-145. 2013 Sep.
6. Ming-Cheh Chen, Chih-Hsun Yi, Li-Yu Wang, Hans Hsienhong Lin, Chi-Tan Hu*. Difference in the Prevalence of CYP2C19 Poor Metabolizers Among Racial and Ethnic Groups of Eastern Taiwan. Gastroenterological Journal of Taiwan 30(4):300-308. 2013 Dec.
7. Jen-Shung Lin, Wen-Lin Lo, Wei-Yi Lei, Hao-Chun Yu, Li-Keng Chao, Rui-Sheng Hong, Dau-Chen Tang, Chi-Tan Hu*. Historic Progress and New Trend of Nasoenteric Tube Placement. Journal of Internal Medicine of Taiwan 24(6):461-468. 2013 Dec.
8. Rong-Nan Chien, Cheng-Yuan Peng, Jia-Horng Kao, Tsung-Hui Hu, Chun-Che Lin, Chi-Tan Hu, Chi-Yi Chen, Tsai-Yuan Hsieh, Han-Chieh Lin, Wan-Long Chuang, on behalf of the Taiwan NA-Registry Group. Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-naïve Taiwanese patients with chronic hepatitis B. Journal of Gastroenterology and Hepatology 29(1):185-192. 2014 Jan.(SCI)
9. Ming-Cheh Chen, Wei-Yi Lei, Jen-Shung Lin, Chih-Hsun Yi, Deng-ChyangWu, Chi-Tan Hu*. Levofloxacin-Amoxicillin/Clavulanate-Rabeprazole versus a Standard Seven-Day Triple Therapy for Eradication of Helicobacter pylori BioMed Research International (Journal of Biomedicine and Biotechnology) 2014(ID 158520):1-7. 2014 Jun. (SCI)
10. Surbhi Jain, Lijia Xie, Batbold Boldbaatar, Selena Y. Lin, James P. Hamilton, Stephen J. Meltzer, Shun-Hua Chen, Chi-Tan Hu, Timothy M. Block, Wei Song*, Ying-Hsiu Su*. Differential methylation of the promoter and first exon of the RASSF1A gene in hepatocarcinogenesis. Hepatology Research 1-14. 2014 Nov. (SCI)

完整著作連結請點此

著作專章/專書:

1. Chi-Tan Hu, CL Chen, Zhen-Xiong Lin. Ch.6 Miscellaneous Disorders. 9. Small Bowel Tapeworm. Atlas of Small Intestinal Disorders: Integrated Case Presentation. P206-209. Ho-Chi Book Publishing Co. 2014 Jan.【ISBN 978-986-368-001-7】
2. 胡志棠. Part 2認識肝硬化發病原因與預防. 2-3肝硬化的症狀及徵兆. 肝硬化全書-全國護肝專家教你預防、照護、治療36-46. 如何出版社有限公司 2014年5月.【ISBN 978-986-136-389-9】
3. 大愛電視台「人體的奧秘系列：人體的超級工廠-肝臟」影片科學顧問（國科會補助） (2014年1月11日首播)

榮譽事項/學術獎勵:

l   87年度同時獲得英國劍橋大學分子生物學及倫敦大學King's College肝病研究中心（Institute of Liver Studies）博士班錄取。

l   93年度慈濟醫學雜誌(第十六卷)優秀論文選拔，基礎醫學組第一名。

l   94年度慈濟醫學雜誌(第十七卷)優秀論文選拔，基礎醫學組第一名。

l   98年度Young Investigator Award(YIA) Section亞太特殊研究獎(Asia Pacific Digestive Week, 27–30 Sep 2009, Taipei International Convention, Center Taipei, Taiwan, New Frontier in Digestive Medicine)

l   99年度第十三屆周大觀文教基金會全球熱愛生命獎章。

l   99年度慈濟醫院研究績效卓越獎資深人員第三名。

l   100年度第一、二期慈濟醫院微笑天使選拔第一名。

l   102年度花蓮慈濟醫院優秀研究論文評選-資深醫師組第三名。

l   103年度慈濟大學醫學系102學年度教學優良教師。

l105年度花蓮慈濟醫院優秀研究論文評選-資深醫師組第三名。

 

專利:

1. 魏誠佑、謝昌衛、盧崑山、夏靜吾、龍輝、蕭正忠、胡志棠。用以治療癌症及／或腫瘤之到手香葉汁 LEAF JUICE OF PLECTRANTHUS AMBOINICUS FOR TREATING CANCER AND/OR TUMOR。（專利證書號數I399210）
2. 高立人、鍾承璋、胡志棠、陳明賢。基於雲端運算技術之影像處理系統。(發明第I498747號)

 

執行計畫（包含產學合作計畫）	補助/委託機構	計畫名稱	起迄日期
	Gilead Sciences, Inc/ PRA廠商委託計畫	A Phase 4, Randomized, Open-label, Active-Controlled,Superiority Study to Evaluate the Efficacy and Safety of TDF in Combination with Peginterferon α-2a (Pegasys®) versus Standard of Care TDF Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Non-Cirrhotic Subjects with HBeAg-Positive or HBeAg-Negative CHB（TCCSP100-05）	100.6.1- 105.12.31
	科技部專題研究計畫	The role of paxillin and Hic-5 in tumor progression of hepatocellular carcinoma	101.8.1- 104.7.31
	Gilead Sciences, Inc/ PRA廠商委託計畫	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of TenofovirAlafenamide (TAF) 25 mg QD versus TenofovirDisoproxilFumarate (TDF) 300 mg QD for the Treatment of HBeAg Negative, Chronic Hepatitis B	103.7.1- 105.12.31
	花蓮慈濟醫院院內計畫	The role of Golgi-localized, gamma-ear-containing, Arf-binding proteins (GGA3) in endosomal signaling for tumor progression of hepatocellular carcinoma	104.1.1- 104.12.31
	Gilead Sciences, Inc/ PRA廠商委託計畫	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of TenofovirAlafenamide (TAF) 25 mg QD versus TenofovirDisoproxilFumarate (TDF) 300 mg QD for the Treatment of HbeAg Positive, Chronic Hepatitis B	104.3.19- 106.12.31
	慈濟醫療志業任務導向之跨院校合作研究計畫	Hic-5作為肝癌惡化指標及治療肝癌之標靶分子	104.8.1- 107.7.31
	科技部專題研究計畫	Preclinical trials for the Ling-Zhi-derived peptide LZ8 to prevent progression of patient-derived hepatoma cells	104.8.1- 106.7.31
	花蓮慈濟醫院院內計畫	The role of regulators of c-Met endocytosis in HGF-induced fluctuant signaling and tumor progression in hepatoma cells	105.1.1- 105.12.31
	國家衛生研究院與花蓮慈濟醫院雙邊合作研究計畫	Integrated Nanodiamond and Small Molecular and Protein Drugs on Zebrafish Biocompatibility and Drug Screening Platform for Personalized Medicine Against Liver Diseases and Cancer	105.8.1- 108.7.31
	花蓮慈濟醫院院內計畫	Ling-Zhi-8 suppress progression of HCC by binding to specific type of N-glycan motif on receptor tyrosin kinase	106.1.1- 107.12.31
	藥華醫藥股份有限公司/ 丘以思生技 廠商委託計畫	一項開放性、隨機分配、有效藥對照試驗：證明P1101併用Ribavirin對於未接受干擾素治療感染C型肝炎病毒基因型第2型患者之療效不劣於PEG-Intron併用Ribavirin，並比較兩者之安全性與耐受性	106.12.1- 111.12.31
	花蓮慈濟醫院院內計畫	LZ-8 經由結合多個酪胺酸激酶受體之 N-聚醣基以抑制 HCC 進展	108.1.1- 108.12.31
	慈濟醫療志業任務導向之跨院校合作研究計畫	Hic-5作為評估肝癌進展之標誌與治療標靶及Ling-Zhi-8之療效指標	108.1.1- 110.12.31

 

相關學會會員資格:

1. 台灣內科醫學會
2. 台灣消化系醫學會
3. 台灣消化系內視鏡醫學會（第八屆、第九屆理事）
4. 台灣肝臟研究學會
5. 中華針灸醫學會

國內外學術期刊與研究審查委員:

1. 慈濟醫學雜誌專題審查
2. Review Manuscript for British Journal of Medicine and Medical Research
3. Reviewer of BMJ

近年重要會議邀請演講:

1. Chi-Tan Hu. Transnasal Endoscopy is not So Simple as You Can Imagine. 7th Global Congress on Gastroenterology and Endoscopy, September 12-14, 2016 at Atlanta, Georgia, USA.
2. Chi-Tan Hu et al. H. pylori Epidemiology, Outcomes, and Treatment. 2017 Digestive Disease Week (Oral), 2017 May 6-9, USA.
3. Chi-Tan Hu et al. EFFICACY OF HIGH-DOSE DUAL THERAPY VERSUS BISMUTH-CONTAINING QUADRUPLE THERAPY FOR FIRST-LINE TREATMENT OF HELICOBACTER PYLORI INFECTION AND AN INTERIM REPORT OF MULTI-CENTER, RANDOMIZED CONTROL STUDY. 2017 Digestive Disease Week (Oral), 2017 May 6-9, USA.
4. Chi-Tan Hu, Chien-Chih Tung, Chun-Jung Lin, I-Nan Kuo, Bor-Ru Lin, Hong-Long Wang, Jin-De Chen, Mu-Liang Cheng, Chia-Tung Shun, Hui-Mi Li, Jui-Sheng Hung, Wei-Yi Lei, Ming Jium Shieh, Jau-Min Wong, John Y. Kao, Jyh-Chin Yang. EFFICACY OF HIGH-DOSE DUAL THERAPY VERSUS BISMUTH QUADRUPLE THERAPY FOR RESCUE TREATMENT OF HELICOBACTER PYLORI INFECTION–AN INTERIM REPORT OF MULTI-CENTER, RANDOMIZED CONTROL STUDY. 2018 Digestive Disease Week (Oral), 2018 June 2-5, USA.